Company / R&D Expense
Imunon, Inc. R&D Expense History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$11.7M
FY2023
5-year range
$10.6M / $13.1M
FY2019-FY2023
Trend
+10.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense returned to growth in FY2023 after 2 years of decline, reaching $12M.
Based on SEC 10-K filings.
$12M in FY2023 with a 5-year CAGR of -2.1%.
Improved from $11M to $12M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -3.5%
- 5-Year CAGR
- -2.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -2.1%, indicating a declining trend.
- In FY2023, r&d expense increased 10.5% year-over-year.
- Peak r&d expense was recorded in FY2018.
- Lowest r&d expense in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $11.7M | +10.5% |
| FY2022 | $10.6M | -6.4% |
| FY2021 | $11.3M | -13.2% |
| FY2020 | $13.1M | +10.1% |
| FY2019 | $11.9M | -9.3% |
| FY2018 | $13.1M | +39.7% |
| FY2015 | $9.4M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026